MEDIF
Price
$0.06
Change
-$0.00 (-0.00%)
Updated
Aug 28 closing price
Capitalization
22.81M
TLRY
Price
$1.47
Change
+$0.10 (+7.30%)
Updated
Aug 28 closing price
Capitalization
1.61B
34 days until earnings call
Interact to see
Advertisement

MEDIF vs TLRY

Header iconMEDIF vs TLRY Comparison
Open Charts MEDIF vs TLRYBanner chart's image
Medipharm Labs
Price$0.06
Change-$0.00 (-0.00%)
Volume$351.37K
Capitalization22.81M
Tilray Brands
Price$1.47
Change+$0.10 (+7.30%)
Volume$86.19M
Capitalization1.61B
MEDIF vs TLRY Comparison Chart in %
Loading...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MEDIF vs. TLRY commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEDIF is a Hold and TLRY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (MEDIF: $0.06 vs. TLRY: $1.47)
Brand notoriety: MEDIF: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: MEDIF: 274% vs. TLRY: 138%
Market capitalization -- MEDIF: $22.81M vs. TLRY: $1.61B
MEDIF [@Pharmaceuticals: Generic] is valued at $22.81M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.61B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEDIF’s FA Score shows that 0 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • MEDIF’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, TLRY is a better buy in the long-term than MEDIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEDIF’s TA Score shows that 3 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • MEDIF’s TA Score: 3 bullish, 7 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TLRY is a better buy in the short-term than MEDIF.

Price Growth

MEDIF (@Pharmaceuticals: Generic) experienced а +4.18% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +32.43% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.15%. For the same industry, the average monthly price growth was +68.06%, and the average quarterly price growth was +81.85%.

Reported Earning Dates

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.62B) has a higher market cap than MEDIF($22.8M). MEDIF YTD gains are higher at: 38.741 vs. TLRY (10.526). MEDIF has higher annual earnings (EBITDA): -4.75M vs. TLRY (-2.13B). TLRY has more cash in the bank: 256M vs. MEDIF (8.44M). MEDIF has less debt than TLRY: MEDIF (125K) vs TLRY (329M). TLRY has higher revenues than MEDIF: TLRY (821M) vs MEDIF (43M).
MEDIFTLRYMEDIF / TLRY
Capitalization22.8M1.62B1%
EBITDA-4.75M-2.13B0%
Gain YTD38.74110.526368%
P/E RatioN/AN/A-
Revenue43M821M5%
Total Cash8.44M256M3%
Total Debt125K329M0%
FUNDAMENTALS RATINGS
MEDIF vs TLRY: Fundamental Ratings
MEDIF
TLRY
OUTLOOK RATING
1..100
7526
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4835
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (53) in the Biotechnology industry is somewhat better than the same rating for MEDIF (91) in the null industry. This means that TLRY’s stock grew somewhat faster than MEDIF’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MEDIF (100) in the null industry. This means that TLRY’s stock grew similarly to MEDIF’s over the last 12 months.

TLRY's SMR Rating (100) in the Biotechnology industry is in the same range as MEDIF (100) in the null industry. This means that TLRY’s stock grew similarly to MEDIF’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is in the same range as MEDIF (48) in the null industry. This means that TLRY’s stock grew similarly to MEDIF’s over the last 12 months.

TLRY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MEDIF (100) in the null industry. This means that TLRY’s stock grew similarly to MEDIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEDIFTLRY
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 25 days ago
84%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AFSIC16.050.30
+1.90%
AmTrust Financial Services, Inc.
SWRAY8.670.04
+0.46%
Swire Pacific Ltd.
ANZLY1.65N/A
N/A
Air New Zealand Ltd.
PGXPF0.11N/A
N/A
Pelangio Exploration Inc.
COOSF11.60N/A
N/A
Carbios SA

MEDIF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEDIF has been loosely correlated with CGC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDIF jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEDIF
1D Price
Change %
MEDIF100%
+2.87%
CGC - MEDIF
36%
Loosely correlated
+24.50%
TLRY - MEDIF
28%
Poorly correlated
+7.30%
ACB - MEDIF
24%
Poorly correlated
+5.44%
AAWH - MEDIF
24%
Poorly correlated
+0.65%
GLASF - MEDIF
24%
Poorly correlated
+1.08%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
+7.30%
SNDL - TLRY
76%
Closely correlated
+6.32%
CGC - TLRY
62%
Loosely correlated
+24.50%
CRON - TLRY
60%
Loosely correlated
+1.56%
OGI - TLRY
60%
Loosely correlated
+3.59%
ACB - TLRY
55%
Loosely correlated
+5.44%
More